These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23036283)

  • 1. Analgesic effects mediated by neuronal nicotinic acetylcholine receptor agonists: correlation with desensitization of α4β2* receptors.
    Zhang J; Xiao YD; Jordan KG; Hammond PS; Van Dyke KM; Mazurov AA; Speake JD; Lippiello PM; James JW; Letchworth SR; Bencherif M; Hauser TA
    Eur J Pharm Sci; 2012 Dec; 47(5):813-23. PubMed ID: 23036283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α4β2 neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of α4β2 nAChR agonists in pain.
    Lee CH; Zhu C; Malysz J; Campbell T; Shaughnessy T; Honore P; Polakowski J; Gopalakrishnan M
    Biochem Pharmacol; 2011 Oct; 82(8):959-66. PubMed ID: 21763685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulation of dopamine release by nicotinic acetylcholine receptor ligands in rat brain slices correlates with the profile of high, but not low, sensitivity alpha4beta2 subunit combination.
    Anderson DJ; Malysz J; Grønlien JH; El Kouhen R; Håkerud M; Wetterstrand C; Briggs CA; Gopalakrishnan M
    Biochem Pharmacol; 2009 Oct; 78(7):844-51. PubMed ID: 19555668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of analgesic efficacy but not side effects: co-administration of an α4β2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats.
    Zhu CZ; Chin CL; Rustay NR; Zhong C; Mikusa J; Chandran P; Salyers A; Gomez E; Simler G; Lewis LG; Gauvin D; Baker S; Pai M; Tovcimak A; Brown J; Komater V; Fox GB; Decker MW; Jacobson PB; Gopalakrishnan M; Lee CH; Honore P
    Biochem Pharmacol; 2011 Oct; 82(8):967-76. PubMed ID: 21620806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive allosteric modulation of α4β2 nAChR agonist induced behaviour.
    Rode F; Munro G; Holst D; Nielsen EØ; Troelsen KB; Timmermann DB; Rønn LC; Grunnet M
    Brain Res; 2012 Jun; 1458():67-75. PubMed ID: 22552114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization.
    Bannon AW; Decker MW; Curzon P; Buckley MJ; Kim DJ; Radek RJ; Lynch JK; Wasicak JT; Lin NH; Arnold WH; Holladay MW; Williams M; Arneric SP
    J Pharmacol Exp Ther; 1998 May; 285(2):787-94. PubMed ID: 9580627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sazetidine-A is a potent and selective agonist at native and recombinant alpha 4 beta 2 nicotinic acetylcholine receptors.
    Zwart R; Carbone AL; Moroni M; Bermudez I; Mogg AJ; Folly EA; Broad LM; Williams AC; Zhang D; Ding C; Heinz BA; Sher E
    Mol Pharmacol; 2008 Jun; 73(6):1838-43. PubMed ID: 18367540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antinociceptive activity of α4β2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain.
    Nirogi R; Jabaris SL; Jayarajan P; Abraham R; Shanmuganathan D; Rasheed MA; Royapalley PK; Goura V
    Eur J Pharmacol; 2011 Oct; 668(1-2):155-62. PubMed ID: 21756895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sazetidine-A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them.
    Xiao Y; Fan H; Musachio JL; Wei ZL; Chellappan SK; Kozikowski AP; Kellar KJ
    Mol Pharmacol; 2006 Oct; 70(4):1454-60. PubMed ID: 16857741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antinociceptive effects of novel epibatidine analogs through activation of α4β2 nicotinic receptors.
    Li W; Cai J; Wang BH; Huang L; Fan J; Wang Y
    Sci China Life Sci; 2018 Jun; 61(6):688-695. PubMed ID: 29435707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A-366833: a novel nicotinonitrile-substituted 3,6-diazabicyclo[3.2.0]-heptane alpha4beta2 nicotinic acetylcholine receptor selective agonist: Synthesis, analgesic efficacy and tolerability profile in animal models.
    Ji J; Bunnelle WH; Anderson DJ; Faltynek C; Dyhring T; Ahring PK; Rueter LE; Curzon P; Buckley MJ; Marsh KC; Kempf-Grote A; Meyer MD
    Biochem Pharmacol; 2007 Oct; 74(8):1253-62. PubMed ID: 17854775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulators of nicotinic acetylcholine receptors as analgesics.
    Jain KK
    Curr Opin Investig Drugs; 2004 Jan; 5(1):76-81. PubMed ID: 14983978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neonicotinic analogues: selective antagonists for α4β2 nicotinic acetylcholine receptors.
    Faundez-Parraguez M; Farias-Rabelo N; Gonzalez-Gutierrez JP; Etcheverry-Berrios A; Alzate-Morales J; Adasme-Carreño F; Varas R; Bermudez I; Iturriaga-Vasquez P
    Bioorg Med Chem; 2013 May; 21(10):2687-94. PubMed ID: 23561269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α4β2* neuronal nicotinic receptor ligands (agonist, partial agonist and positive allosteric modulators) as therapeutic prospects for pain.
    Nirogi R; Goura V; Abraham R; Jayarajan P
    Eur J Pharmacol; 2013 Jul; 712(1-3):22-9. PubMed ID: 23660369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The unique α4+/-α4 agonist binding site in (α4)3(β2)2 subtype nicotinic acetylcholine receptors permits differential agonist desensitization pharmacology versus the (α4)2(β2)3 subtype.
    Eaton JB; Lucero LM; Stratton H; Chang Y; Cooper JF; Lindstrom JM; Lukas RJ; Whiteaker P
    J Pharmacol Exp Ther; 2014 Jan; 348(1):46-58. PubMed ID: 24190916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.
    Rollema H; Hurst RS
    Psychopharmacology (Berl); 2018 Sep; 235(9):2479-2505. PubMed ID: 29980822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-I A-85380 and TC-2559 differentially activate heterologously expressed alpha4beta2 nicotinic receptors.
    Zwart R; Broad LM; Xi Q; Lee M; Moroni M; Bermudez I; Sher E
    Eur J Pharmacol; 2006 Jun; 539(1-2):10-7. PubMed ID: 16674940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests.
    Andreasen JT; Olsen GM; Wiborg O; Redrobe JP
    J Psychopharmacol; 2009 Sep; 23(7):797-804. PubMed ID: 18583432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antinociceptive effects of nicotinic partial agonists varenicline and sazetidine-A in murine acute and tonic pain models.
    AlSharari SD; Carroll FI; McIntosh JM; Damaj MI
    J Pharmacol Exp Ther; 2012 Sep; 342(3):742-9. PubMed ID: 22678099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective potentiation of gabapentin-mediated antinociception in the rat formalin test by the nicotinic acetylcholine receptor agonist ABT-594.
    Munro G; Dyhr H; Grunnet M
    Neuropharmacology; 2010 Sep; 59(3):208-17. PubMed ID: 20562022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.